⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BBIO News
BridgeBio Pharma, Inc. Common Stock
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
globenewswire.com
BBIO
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
BBIO
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
BBIO
Form 8-K
sec.gov
BBIO
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
globenewswire.com
BBIO
BridgeBio to Participate in March Investor Conferences
globenewswire.com
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
BBIO
Muscular Dystrophy Association Announces Łukasz Sznajder, PhD, MSc, to Receive Inaugural MDA Research Momentum Award
globenewswire.com
ARX
BIIB
BBIO
NVS
RGNX
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
globenewswire.com
BBIO
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO